These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Neuroenhancement: wisdom of the masses or "false phronesis"? Larriviere D; Williams MA Clin Pharmacol Ther; 2010 Oct; 88(4):459-61. PubMed ID: 20856244 [TBL] [Abstract][Full Text] [Related]
43. American culture and neuro-cognitive enhancing drugs. Flaskerud JH Issues Ment Health Nurs; 2010 Jan; 31(1):62-3. PubMed ID: 19951164 [No Abstract] [Full Text] [Related]
44. Freedom to box. Warburton N J Med Ethics; 1998 Feb; 24(1):56-60. PubMed ID: 9549684 [TBL] [Abstract][Full Text] [Related]
45. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Boot BP; Partridge B; Hall W Neurocase; 2012 Jun; 18(3):181-4. PubMed ID: 22007842 [TBL] [Abstract][Full Text] [Related]
46. Moral and social reasons to acknowledge the use of cognitive enhancers in competitive-selective contexts. Garasic MD; Lavazza A BMC Med Ethics; 2016 Mar; 17():18. PubMed ID: 27025299 [TBL] [Abstract][Full Text] [Related]
47. Neuroenhancing public health. Shaw D J Med Ethics; 2014 Jun; 40(6):389-91. PubMed ID: 23793059 [TBL] [Abstract][Full Text] [Related]
48. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. Romanelli MN; Galeotti N; Ghelardini C; Manetti D; Martini E; Gualtieri F CNS Drug Rev; 2006; 12(1):39-52. PubMed ID: 16834757 [TBL] [Abstract][Full Text] [Related]
49. Cognitive enhancers--performance or problem? Sharp C Occup Med (Lond); 2016 Mar; 66(2):88-9. PubMed ID: 26892595 [No Abstract] [Full Text] [Related]
50. Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings. Gualtieri F J Enzyme Inhib Med Chem; 2016; 31(2):187-94. PubMed ID: 25831025 [TBL] [Abstract][Full Text] [Related]
51. Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. Forlini C; Hall W; Maxwell B; Outram SM; Reiner PB; Repantis D; Schermer M; Racine E EMBO Rep; 2013 Feb; 14(2):123-8. PubMed ID: 23318628 [No Abstract] [Full Text] [Related]
52. Drugs, games, and devices for enhancing cognition: implications for work and society. Brühl AB; Sahakian BJ Ann N Y Acad Sci; 2016 Apr; 1369(1):195-217. PubMed ID: 27043232 [TBL] [Abstract][Full Text] [Related]
53. The Use of Pharmacologic Cognitive Enhancers in Competitive Chess. Franke AG; Dietz P; Ranft K; Balló H; Simon P; Lieb K Epidemiology; 2017 Nov; 28(6):e57-e58. PubMed ID: 28817470 [No Abstract] [Full Text] [Related]
54. [The use of encephabol in neurological practice]. Damulin IV Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(6):53-6. PubMed ID: 12101897 [No Abstract] [Full Text] [Related]
55. [Cognition on demand?--The wish for cognition-enhancing drugs in medicine]. Synofzik M Ethik Med; 2006 Mar; 18(1):37-50. PubMed ID: 17153250 [TBL] [Abstract][Full Text] [Related]
56. Cognition enhancing drugs ('nootropics'): time to include coaches and team executives in doping tests? Rodenberg RM; Holden JT Br J Sports Med; 2017 Sep; 51(18):1316. PubMed ID: 26809260 [No Abstract] [Full Text] [Related]
57. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Larriviere D; Williams MA; Rizzo M; Bonnie RJ; Neurology; 2009 Oct; 73(17):1406-12. PubMed ID: 19776378 [TBL] [Abstract][Full Text] [Related]
59. AGAINST PATERNALISTIC VIEWS ON NEUROENHANCEMENT: A LIBERTARIAN EVOLUTIONARY ACCOUNT. Corbellini G; Sirgiovanni E Med Secoli; 2015; 27(3):1089-110. PubMed ID: 27348994 [TBL] [Abstract][Full Text] [Related]